Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 4/20 | 0.56 |
| ▸ | CTSL | P07711 | 4/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29935714 | 1.00 | CTSV (0.56) | CTSVCTSLABCB1MAPTMEN1 | |
| SCHEMBL21775128 | 0.88 | SMN1; SMN2 (0.65) | CTSVCTSLABCB1MAPTMEN1 | |
| SCHEMBL4593234 | 0.88 | CTSV (0.56) | CTSVCTSLABCB1MAPTMEN1 | |
| SCHEMBL750245 | 0.87 | CTSV (0.63) | CTSVCTSLABCB1MAPTMEN1 | |
| SCHEMBL31582278 | 0.85 | ABCB1 (0.57) | CTSVCTSLABCB1MAPTMEN1 | |
| SCHEMBL1446822 | 0.85 | PTGES (0.48) | CTSVCTSLABCB1MAPTMEN1 | |
| SCHEMBL965943 | 0.85 | ALDH1A1 (0.63) | CTSVCTSLABCB1MAPTMEN1 | |
| SCHEMBL750963 | 0.85 | CTSV (0.58) | CTSVCTSLABCB1MAPTMEN1 | |
| SCHEMBL16004968 | 0.85 | ABCB1 (0.59) | CTSVCTSLABCB1MAPTMEN1 | |
| SCHEMBL9658186 | 0.85 | CTSV (0.58) | CTSVCTSLABCB1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115873909-B | Preparation method of arformoterol chiral intermediate | 天津法莫西生物医药科技有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-115873909-A | Preparation method of arformoterol chiral intermediate | 天津法莫西生物医药科技有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-115093329-A | Preparation method of 1- (4- (benzyloxy) -3-nitrophenyl) -2-bromoethanone | 汉瑞药业(荆门)有限公司 | 2022-09-23 | — | — | CN | claimed |
| CN-112279776-B | Method for synthesizing arformoterol free alkali | 扬州中宝药业股份有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-108358791-A | A kind of preparation method of 3- nitros -4- benzyloxy -2- bromoacetophenones | 南京法恩化学有限公司 | 2018-08-03 | — | — | CN | claimed |
| EP-0938467-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE ISOMERS OF FORMOTEROL | SEPRACOR INC (US) | 2002-06-12 | — | — | EP | claimed |
| US-6268533-B1 | REACTING 4-BENZYLOXY-3-FORMAMIDOSTYRENE OXIDE WITH AN OPTICALLY PURE 4-METHOXY-.ALPHA.-METHYL-N-(PHENYLMETHYL)BENZENEETHANAMINE FOLLOWED BY REDUCTION TO PRODUCE FORMOTEROL | SEPRACOR INC. | 2001-07-31 | — | — | US | claimed |
| EP-0938467-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE ISOMERS OF FORMOTEROL | SEPRACOR, INC. (US) | 1999-09-01 | — | — | EP | claimed |
| WO-1998021175-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE ISOMERS OF FORMOTEROL | SEPRACOR, INC. (US) | 1998-05-22 | — | — | WO | claimed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| CN-115873909-B | Preparation method of arformoterol chiral intermediate | 天津法莫西生物医药科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-115873909-B | Preparation method of arformoterol chiral intermediate | 天津法莫西生物医药科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-4192830-A1 | 2-(4-((5-(BENZO[B]THIOPHEN-3-YL)-1H-TETRAZOL-1-YL)METHYL)PHENYL)-5-(DIFLUOROMETHYL)-1,3,4-OXADIAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) FOR USE IN TREATING E.G. PERIPHERAL NEUROPATHY | Italfarmaco SpA (IT) | 2023-06-14 | — | — | EP | disclosed |
| CN-113801005-B | Preparation method of alpha-bromoacetophenone compound | 浙江师范大学 | 2023-06-13 | — | — | CN | disclosed |
| US-4654371-A | ANTI-OBESITY, HYPOGLYCEMIA AGENTS | BEECHAM GROUP P.L.C. (GB) | 1987-03-31 | — | — | US | disclosed |
| US-4478849-A | HYPERGLYCEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1984-10-23 | — | — | US | disclosed |
| EP-0006735-B1 | SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
| US-3994974-A | BRONCHODILATORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-11-30 | — | — | US | disclosed |
| US-3933913-A | N,N'-bis[3-substituted-4-hydroxypheyl)-2-hydroxyethyl)]-polymethylenediamines | SMITHKLINE CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | CTSV 3155/4885CTSL 4283/4885ABCB1 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.